MARKET

IONS

IONS

Ionis Pharmaceuticals
NASDAQ
45.36
+1.38
+3.14%
After Hours: 45.20 -0.16 -0.35% 19:56 02/23 EST
OPEN
44.09
PREV CLOSE
43.98
HIGH
45.39
LOW
44.02
VOLUME
1.70M
TURNOVER
0
52 WEEK HIGH
54.44
52 WEEK LOW
32.69
MARKET CAP
6.51B
P/E (TTM)
-17.7326
1D
5D
1M
3M
1Y
5Y
Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Seeking Alpha · 2d ago
Bullish Two Hundred Day Moving Average Cross - IONS
NASDAQ · 2d ago
Biogen granted EU backing for ALS therapy
Biogen granted EU backing for ALS therapy. European Medicines Agency endorsed its antisense oligonucleotide Qalsody as a treatment for amyotrophic lateral sclerosis. The drug is a rare neurodegenerative condition. Biogen markets the therapy as part of a licensing agreement with Ionis Pharmaceuticals.
Seeking Alpha · 2d ago
S&P 500 Futures Steady In Premarket Trading; Carvana, Block Lead
U.S. Stock markets set to open in two hours. Carvana up 30.5% in pre-market trading. S&P 500 futures were up 0.00%. Brent crude oil futures were down 1.34%. Bitcoin slipped 1.94% to $50,956.
Barron‘s · 2d ago
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
NASDAQ · 3d ago
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
Ionis Pharmaceuticals has been analyzed by 7 analysts in the last three months. The company has an average price target of $59.86. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. The average 12-month price target for the company is $50.00.
Benzinga · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nevro Corp (NVRO), Silver Spike Investment (SSIC) and Ionis Pharmaceuticals (IONS)
TipRanks · 3d ago
Ionis Pharmaceuticals: A Strong Buy on ATTR Franchise Prospects and Financial Fortitude
TipRanks · 3d ago
More
About IONS
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on cardiovascular and neurology franchises. The Company’s products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The Company has over seven medicines in Phase III studies for nine indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)), Tofersen (SOD1) and Bepirovirsen. Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, Fesomersen, ION904 and IONIS-AGT-LRx.

Webull offers Ionis Pharmaceuticals Inc stock information, including NASDAQ: IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.